New UK Tool Predicts Risk of Obesity-Related Diseases

Researchers from Queen Mary University of London and the Berlin Institute of Health have developed a new risk-prediction tool designed to identify individuals at high risk of developing serious obesity-related complications. The tool, named Obscore, aims to provide a more personalized approach to health monitoring and the allocation of medical interventions than traditional metrics.

Obscore is intended to complement the body mass index (BMI), which has long been the primary measure for identifying obesity risk. By identifying those most susceptible to complications such as type 2 diabetes and cancer, the tool may allow healthcare providers to implement proactive interventions, including the use of weight-loss medications, for individuals who might not otherwise meet the strict criteria for such treatments.

Methodology and Development

The development of the tool involved the analysis of extensive data from 200,000 middle-aged adults who participated in the UK Biobank study. Researchers examined more than 2,000 health factors, which ranged from basic demographics like age and sex to complex blood biomarkers.

The study specifically focused on individuals with a BMI of 27 or higher. This group is classified as overweight but not necessarily obese. Researchers included this population because some individuals in this category possess excess body fat that can lead to significant metabolic complications despite not meeting the clinical definition of obesity.

The resulting model, published in Nature Medicine, identified 20 commonly collected health measures that can predict 18 different obesity-related complications. Obscore categorizes individuals into low- and high-risk groups based on these measures.

Clinical Application and Resource Allocation

The tool has significant implications for the National Health Service (NHS) in England, where approximately two-thirds of adults are overweight or obese. Currently, access to weight-loss medications on the NHS is limited and generally based on a combination of high BMI and the presence of specific obesity-related health problems.

Researchers suggest that Obscore could help the NHS prioritize who receives these limited resources by identifying those most likely to benefit from the therapy.

It’s about developing and validating a score that can help with more rational resource allocation. So, can we prescribe therapy to those people who are most likely to need it and most likely to benefit from it – which is what we should do within the NHS,

Prof Nick Wareham, University of Cambridge

Prof Wareham, a co-author of the study, clarified that the goal is not to simply extend the use of specific therapies to more people, but to ensure the most appropriate patients receive them.

Identifying Overlooked Populations

A key finding of the research was that a considerable proportion of the individuals in the highest-risk group were living with overweight rather than obesity. This suggests that relying solely on BMI can result in a failure to identify high-risk patients who require early monitoring or intervention.

These constitute a population of individuals who may be overlooked if we only look at BMI and not other risk factors….

Dr Kamil Demircan, Queen Mary University of London

By utilizing 20 health measures rather than a single metric, Obscore provides a more nuanced view of metabolic health. This open-access tool is designed to help clinicians move toward a more rational, data-driven approach to treating obesity-related risks before severe complications develop.